Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
225 hedge funds and large institutions have $2.17B invested in Sage Therapeutics in 2021 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 90 increasing their positions, 68 reducing their positions, and 58 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 68
3.18% less ownership
Funds ownership: 86.62% → 83.45% (-3.2%)
12% less funds holding
Funds holding: 256 → 225 (-31)
24% less capital invested
Capital invested by funds: $2.88B → $2.17B (-$702M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
45% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 58
55% less call options, than puts
Call options by funds: $15.4M | Put options by funds: $34.5M
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$43.9M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$38.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$29.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$24.3M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$16.9M |
Top Sellers
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$86.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$56.2M |
| 3 |
DKCM
Davidson Kempner Capital Management
New York
|
-$43.3M |
| 4 |
Jennison Associates
New York
|
-$33.1M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$27.9M |
SAGE Hedge Fund Activity: Q3 2021 in Review
225 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2021, worth a combined $2.17B — down 24% from $2.88B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of SAGE and 32 opened new positions — a net loss of 26 holders — while 68 trimmed existing stakes and 90 added.
The largest buyer was Wellington Management Group, adding an estimated $43.9M. The largest seller was Artisan Partners, exiting entirely with an estimated $86.4M sold.
- 225 institutional investors held Sage Therapeutics (SAGE) as of Q3 2021, down from 256 in Q2 2021.
- Funds reported $2.17B of Sage Therapeutics stock for Q3 2021, down 24% quarter-over-quarter.
- 32 funds opened new Sage Therapeutics positions in Q3 2021 and 58 closed out, a net change of -26 holders.
- The largest Sage Therapeutics buyer in Q3 2021 was Wellington Management Group, an estimated $43.9M added.
- The largest Sage Therapeutics seller in Q3 2021 was Artisan Partners, an estimated $86.4M sold.
Based on aggregated 13F filings for Q3 2021.